CD4 and type 2 diabetes mellitus: Given that an impaired CD4+T cell differentiation was detected after the first dose of BNT162b2 vaccination, it is possible that the poor vaccine efficacy with CoronaVac among patients with type 2 diabetes is also related to a compromised initial CD4+T cell response.